Derivative exercise or conversion — not an open-market buy.
Traded Nov 3, 2025 · Filed Nov 4, 2025
Boston Scientific's & Group Pres, Cardiology sold $1.69M of Boston Scientific shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,688,749
Shares × reported transaction price
12 days after results of Oct 22, 2025, 93 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $98.59 on Nov 3, 2025, 16% above its 52-week low and 9% below its high, after a 2% rise over the previous 30 trading days
52-week range $84.72 (Nov 4, 2024) to $108.14 (Sep 8, 2025), 59% of the way up, from 250 adjusted closes. 30 trading days earlier: $97.03 on Sep 22, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +5.3% | +0.9% | +4.4% |
| 30 days | -1.4% | +1.2% | -2.6% |
| 90 days | -7.4% | +1.8% | -9.1% |
| 180 days | -42.5% | +6.0% | -48.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.